[GALE] Galena Biopharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 74.55 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.98 Change: 0.03 (1.54%)
Ext. hours: Change: 0 (0%)

chart GALE

Refresh chart

Strongest Trends Summary For GALE

GALE is in the long-term down -100% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company?s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding181.84 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.98% Sales Growth - Q/Q-13.93% P/E
P/E To EPS Growth P/S7.53 P/BV1.26 Price/Cash Per Share
Price/Free Cash Flow ROA-41.07% ROE-75.5% ROI-64.1%
Current Ratio1.69 Quick Ratio1.67 Long Term Debt/Equity0.15 Debt Ratio0.57
Gross Margin85.2% Operating Margin-520.4% Net Profit Margin-450.76% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities41.28 M Cash From Investing Activities-520 K Cash From Operating Activities-11.56 M Gross Profit2.36 M
Net Profit-10.54 M Operating Profit-11.45 M Total Assets108.61 M Total Current Assets57.32 M
Total Current Liabilities33.96 M Total Debt7.53 M Total Liabilities49.52 M Total Revenue2.75 M
Technical Data
High 52 week600 Low 52 week0.26 Last close600 Last change0%
RSI99.99 Average true range42.86 Beta0.79 Volume380.29 K
Simple moving average 20 days232.97% Simple moving average 50 days730.34% Simple moving average 200 days3154%
Performance Data
Performance Week0% Performance Month222122% Performance Quart139435% Performance Half107043%
Performance Year29456.7% Performance Year-to-date230669% Volatility daily165.01% Volatility weekly368.98%
Volatility monthly756.17% Volatility yearly2619.46% Relative Volume216.5% Average Volume815.19 K
New High New Low

News

2018-11-15 13:47:48 | Edited Transcript of GALE earnings conference call or presentation 15-Nov-18 1:00pm GMT

2018-02-13 12:49:16 | Why Galena Biopharma Inc’s NASDAQ:GALE Investor Composition Impacts Your Returns

2018-01-03 07:50:00 | Blog Exposure - Galena Biopharma’s Stockholders Approve Business Combination with SELLAS Life Sciences Group

2018-01-02 08:09:09 | How Does Galena Biopharma Inc NASDAQ:GALE Affect Your Portfolio Returns?

2017-12-29 10:16:24 | Company Update NASDAQ:GALE: Galena Biopharma Inc Shares Are Racing Up the Market 17%; Here’s Why

2017-12-29 09:25:00 | Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock Split Ratio

2017-12-14 17:03:38 | Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote

2017-12-08 14:50:37 | Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017

2017-11-30 15:05:08 | Where Galena Biopharma Inc GALE Stands In Terms Of Earnings Growth Against Its Industry

2017-11-09 19:53:35 | Galena Biopharma reports 3Q loss

2017-11-09 16:30:00 | Galena Biopharma Reports Third Quarter 2017 Financial Results

2017-10-31 18:34:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE

2017-10-20 08:36:13 | Is Galena Biopharma Inc’s GALE Balance Sheet A Threat To Its Future?

2017-10-02 07:35:00 | SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

2017-09-28 07:05:00 | Galena Biopharma Announces Completion of Enrollment in Two NeuVax™ nelipepimut-S Clinical Trials in Combination with Trastuzumab

2017-09-20 09:45:19 | How Does Investing In Galena Biopharma Inc GALE Impact Your Portfolio?

2017-09-11 07:05:00 | Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership

2017-09-08 16:36:08 | Galena settles U.S. kickback charges related to opioid drug

2017-08-14 21:54:44 | Galena Biopharma reports 2Q loss

2017-08-14 16:30:00 | Galena Biopharma Reports Second Quarter 2017 Financial Results

2017-08-10 07:00:00 | Featured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group

2017-08-09 08:10:00 | Today's Research Reports on Stocks to Watch: Depomed Inc. and Galena Biopharma

2017-08-08 06:00:00 | Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group

2017-07-12 06:30:00 | Galena Biopharma Provides Corporate Update

2017-06-29 12:26:09 | Top 10 Penny Stocks To Buy in 2017

2017-05-15 10:30:02 | AbbVie and J&J Present Positive Imbruvica Leukemia Data

2017-05-10 18:06:27 | Galena Biopharma reports 1Q loss

2017-05-10 16:30:00 | Galena Biopharma Reports First Quarter 2017 Financial Results

2017-05-10 13:52:05 | Prothena PRTA Q1 Loss Narrower than Expected, Updates View

2017-05-05 10:06:02 | Juno Therapeutics JUNO Posts Wider-than-Expected Q1 Loss

2017-05-05 10:04:02 | Agios AGIO Q1 Loss Narrower than Expected, Indhifa in Focus

2017-04-21 09:30:01 | Zacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products

2017-04-19 10:38:02 | Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

2017-04-13 10:10:00 | DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. GALE & Lead Plaintiff Deadline - April 14, 2017

2017-04-12 15:45:00 | FRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm

2017-04-12 13:34:00 | GALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE

2017-04-11 13:46:00 | For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

2017-04-10 15:26:36 | SEC Targets Fraud on Stock Tip-Sheet Websites

2017-04-10 14:00:00 | 4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm

2017-04-10 11:55:00 | SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Galena Biopharma, Inc. to Contact the Firm

2017-04-05 13:52:00 | Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.

2017-04-05 10:37:00 | DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. GALE and Lead Plaintiff Deadline - April 14, 2017

2017-04-05 09:30:01 | Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy

2017-04-04 13:43:00 | April 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Galena Biopharma, Inc. Investors of Upcoming Lead Plaintiff Deadline

2017-04-04 11:49:00 | Galena's Breast Cancer Drug Combo Deemed Safe

2017-04-04 07:05:00 | Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ nelipepimut-S Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017

2017-04-03 17:26:32 | GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib

2017-04-03 15:47:00 | SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Galena Biopharma, Inc. To Contact The Firm

2017-03-31 17:20:00 | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Galena Biopharma, Inc. - GALE

2017-03-30 11:30:03 | Acorda Presents Data for Parkinson's Candidate CVT-301